Life Sciences / Biotech
The intellectual property lawyers and technical specialists of the Life Sciences/Biotech Practice Group use their legal, biotechnology and life sciences skills to evaluate current technologies and provide expert advice on intellectual property strategy and business development. They have years of experience in the pharmaceutical industry, technology transfer and licensing, life sciences patents and conducting intellectual property audits and due diligence studies. In addition to providing a full range of Life Sciences patent services, our clients look to us for licensing their technology or developing internal intellectual property policies and procedures.
The practice group includes patent attorneys and technical advisors who have years of experience and expertise in biotechnology, bioinformatics, immunology, agricultural biotechnology, gene therapy, genomics, medical devices, diagnostics, pharmaceuticals, proteomics, vaccines and drug delivery.
Many of our group members hold doctorate or advanced scientific degrees in immunology, biochemistry, botany, biotechnology and molecular biology. Many have worked as examiners at the United States Patent and Trademark Office (USPTO) or have held various positions in industry as researchers or in-house counsel.
We understand the complex USPTO procedures, as well as the scientific and business issues. This is what makes the difference for you. BSKB provides uniquely insightful technical advice and intellectual property legal counsel to a growing list of clients who enjoy the benefits of that added value.
Attorneys and Professionals
July 7, 2021
MaryAnne Armstrong discusses whether the same tests for non-obviousness of biotech patents will be applied to pharma inventions developed using AI.
June 17, 2021
MaryAnne Armstrong, Ph. D., sits down with LSIPR to discuss artificial intelligence's impact on IP industry relating to life sciences and pharmaceuticals.
September 23, 2021
Effective January 1, 2022, a USPTO surcharge fee of $400 (large entity), $200 (small entity) and $100 (micro entity) will apply for non-DOCX filings. The surcharge fee applies to utility non-provisional application filings (e.g., the specification, claims, and abstract must be in DOCX format to avoid the surcharge; drawings are not subject to this requirement). The DOCX surcharge does not apply to US National Stage Applications or PCT International Applications filed in the US Receiving Office. Drawings may be filed as PDF or DOCX documents. There is no surcharge for drawings not filed as DOCX documents. DOCX is a structured text-based Microsoft Word document. To avoid the USPTO surcharge, our policy at BSKB will be to require a DOCX format for all utility non-provisional applications (preferred for National Stage and PCT applications, but not required) filed on or after January 1, 2022. The USPTO already accepts DOCX filings, and we recommend that you commence sending applications in DOCX format as soon as possible.
May 28, 2021
Leonard Svensson recently published an article in IPWatchdog, Inc. analyzing meat substitution companies and the patent protection being sought and obtained in the industry.